Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519, a B7-H3 targeting miniprotein radioconjugate, in patients with metastatic castration-resistant prostate cancer. The two-trial strategy includes an mCRPC-dedicated study and a separate basket trial for lung, colorectal, and other solid tumors slated for the second half of 2026.
Key figures
- Drug Name
- AKY-2519
- Phase Of Trial
- Phase 1b
- Assets in clinic
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.